Product logins

Find logins to all Clarivate products below.


The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with these therapies usually relegated to later lines because of their higher prices, duration restrictions, and/or injectable mode of delivery. Additionally, osteoporosis diagnosis and compliance rates are low mainly because of patients’ concern about rare but serious side effects of medications, the asymptomatic nature of the disease, and a limited understanding of the seriousness of osteoporosis. However, despite these obstacles, select branded therapies have achieved significant sales. Opportunities exist for emerging agents in osteoporosis, but these agents will likely face challenges.

QUESTIONS ANSWERED

  • What is the current patient share of branded therapies such as Eli Lilly’s Forteo and Amgen’s Prolia?
  • What effect has the launch of Radius Health’s Tymlos had on treatment decisions?
  • What are the anticipated changes in prescribing patterns over the next 12 months?
  • What effect do physicians think the launch of Amgen / UCB’s Evenity would have? Which patients would most likely be prescribed Evenity? Which current therapies would be most affected by Evenity’s launch?
  • What are U.S. specialists’ attitudes and perceptions regarding diagnosis and treatment of osteoporosis?
  • What are the drivers and constraints determining prescribing practices for osteoporosis?

Scope

  • Geography: United States.
  • Primary Research: Survey of 100 U.S. rheumatologists / endocrinologists / PCPs.
  • Key Drugs Covered: Prolia, Tymlos, Forteo, oral and IV bisphosphonates, SERMs, HRT, calcitonin.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…